These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37280588)

  • 1. Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study.
    Antoniou T; Pritlove C; Shearer D; Tadrous M; Shah H; Gomes T
    Int J Equity Health; 2023 Jun; 22(1):112. PubMed ID: 37280588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Drug Policy; 2021 Oct; 96():103238. PubMed ID: 33902968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
    Goodyear T; Ti L; Carrieri P; Small W; Knight R
    Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
    Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
    Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
    Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Apparently, you can only be treated once": A qualitative study exploring perceptions of hepatitis C and access to treatment among people who inject drugs visiting a needle and syringe program.
    Fontaine G; Presseau J; Bruneau J; Patey AM; van Allen Z; Mortazhejri S; Høj SB; Hung JC; Grimshaw JM
    Int J Drug Policy; 2023 Nov; 121():104124. PubMed ID: 37451942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "I want to feel young again": experiences and perspectives of young people who inject drugs living with hepatitis C in Vancouver, Canada.
    Jacob J; Goodyear T; Coulaud PJ; Hoong P; Ti L; Knight R
    Can J Public Health; 2021 Oct; 112(5):947-956. PubMed ID: 34115340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
    Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
    BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis.
    Amoako A; Ortiz-Paredes D; Engler K; Lebouché B; Klein MB
    Int J Drug Policy; 2021 Oct; 96():103247. PubMed ID: 33853727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general practice settings in Australia.
    Heard E; Smirnov A; Massi L; Selvey LA
    J Subst Abuse Treat; 2021 Aug; 127():108460. PubMed ID: 34134878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment for hepatitis C virus with direct acting antiviral agents: Perspectives and treatment experiences of people who inject drugs.
    Karasz A; Singh R; McKee MD; Merchant K; Kim AY; Page K; Pericot-Valverde I; Stein ES; Taylor LE; Wagner K; Litwin AH
    J Subst Abuse Treat; 2022 Sep; 140():108768. PubMed ID: 35729038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene.
    Gunn J; McNally S; Ryan J; Layton C; Bryant M; Walker S; O'Mahony C; Pedrana A
    Int J Drug Policy; 2021 Oct; 96():103387. PubMed ID: 34330571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly collection.
    Beer L; Inglis S; Malaguti A; Byrne C; Sharkey C; Robinson E; Gillings K; Radley A; Hapca A; Stephens B; Dillon J
    J Viral Hepat; 2022 Aug; 29(8):646-653. PubMed ID: 35582875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
    J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.
    Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
    Int J Drug Policy; 2023 Jan; 111():103917. PubMed ID: 36542883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs.
    E Williams B; Nelons D; Seaman A; Witkowska M; Ronan W; Wheelock H; Zaman A; Garcia J
    Int J Drug Policy; 2019 Oct; 72():138-145. PubMed ID: 30995968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transformation of identity in substance use as a pathway to recovery and the potential of treatment for hepatitis C: a systematic review.
    Donaldson SR; Radley A; Dillon JF
    Addiction; 2023 Mar; 118(3):425-437. PubMed ID: 35993427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
    Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
    Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.